"A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Study to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729) in Pediatric Participants (ages 10 to 17 years, inclusive) with Type 2 Diabetes Mellitus"

drug protocol number
MK-8835-059-00
drug sponsor
MSD
drug study
Ertugliflozin
drug trial site
KSH
drug status
Ongoing
drug phase